Upcoming Catalysts
- FDA approval of BA and BA+EZ (Feb. '20)
- EMA approval of BA and BA+EZ (1Q '20)
- BA marketization & revenue earnings (2H '20)
- CVOT data (2023)
Introduction
Shares of Esperion Therapeutics (ESPR) are up 64% and nearly 50% relative to the general market (SPY) since I penned my introductory article, "Low Risk And Primed For Substantial Growth" in October 2019:
Coupled with an unusually bullish biotech market, investors appear to be betting on the upcoming FDA approval and drug launch. Furthermore, the bearish thesis surrounding an investment in Esperion (safety